Rapidly progressive destructive arthritis in psoriatic arthritis sine psoriasis: do bone resorption marker levels predict outcome of bone destruction in psoriatic arthritis?
Taniguchi
Yoshinori
Y
Department of Endocrinology, Metabolism and Nephrology, Kochi Medical School, Kochi University, Kohasu, Oko-cho, Nankoku, Kochi, 783-8505, Japan. yoshii_tan@yahoo.co.jp
Kumon
Yoshitaka
Y
Shimamura
Yoshiko
Y
Kobayashi
Shigeto
S
Terada
Yoshio
Y
D000469:Alkaline Phosphatase / Q000097:blood; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D015535:Arthritis, Psoriatic / Q000175:diagnosis* / Q000188:drug therapy / Q000378:metabolism; D015415:Biomarkers / Q000378:metabolism; D001862:Bone Resorption / Q000378:metabolism / Q000473:pathology*; D024042:Collagen Type I / Q000097:blood / Q000652:urine; D018450:Disease Progression; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D000069285:Infliximab; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D010455:Peptides / Q000097:blood / Q000652:urine; D011379:Prognosis; D011565:Psoriasis
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D015415:Biomarkers; D024042:Collagen Type I; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide; D000069285:Infliximab; D000469:Alkaline Phosphatase; D008727:Methotrexate